Medicare Enrolled
Dr. Jewel Johl, M.D.
Hematology & Oncology · Walnut Creek, CA
Practice pattern: Mixed Practice
— Diverse clinical practice across multiple procedure types
Speaking/Promotional
Very High
DATA COVERAGE
Data in 4 of 4 federal sources
Measures public federal data availability — not provider quality
Informational, not a quality rating.
This page presents federal public records about Dr. Johl from CMS (NPPES, Open Payments, Medicare Provider Utilization, PECOS). It is not medical advice, an endorsement, or a judgment of clinical quality. Always consult the provider directly and a licensed clinician for medical decisions. Read methodology →
Are you Dr. Johl?
Request a correction or review of any data shown here. Provider portal →
What this data tells you about Dr. Johl
Dr. Jewel Johl is a hematology & oncology specialist in Walnut Creek, CA, with 20 years of NPI registration. Based on federal Medicare data, Dr. Johl performed 71,115 Medicare services across 2,261 unique beneficiaries.
Between the years covered by Open Payments, Dr. Johl received a total of $280,342 from 78 pharmaceutical and/or device companies across 666 individual payments. These payments are legal, publicly disclosed under the federal Sunshine Act, and common in hematology & oncology. The majority of payments are for speaking programs and promotional activities, reflecting participation in industry-sponsored events. Patients may wish to discuss these relationships with their provider.
The Data Coverage level for Dr. Johl is Very High — reflecting how much public federal data is available about this provider. Patients are encouraged to use this data as one of several factors when choosing a healthcare provider.
✓ 20 years in practice
▲ Top 10% volume in CA
$280,342 industry payments
Medicare Practice Summary
Medicare Utilization ↗71,115
Medicare services
Top 10% in CA for hematology & oncology
2,261
Unique beneficiaries
$27
Avg. Medicare payment
Medicare patients only (65+ / disabled) · How to read this →
~3,556 Medicare services per year of practice
Top procedures by volume
Ranked by number of services performed for Medicare patients. Avg. submitted charge is what the provider billed; avg. Medicare payment is what CMS paid.
| Procedure | Volume | Avg. paid | Avg. submitted |
|---|---|---|---|
| Pembrolizumab injection (Keytruda) | 21,000 | $43 | $126 |
| Anti-nausea injection (fosaprepitant) An injection of fosaprepitant, a medication used to prevent nausea and vomiting. |
13,800 | $0 | $6 |
| Daratumumab injection (Darzalex) An injection containing daratumumab and hyaluronidase-fihj administered under the skin. |
9,900 | $38 | $159 |
| Epoetin alfa injection (Procrit) for anemia An injection of epoetin alfa containing 1000 units for use in patients not on end-stage renal disease (ESRD) dialysis. |
7,900 | $6 | $48 |
| Denosumab injection (Prolia/Xgeva) | 3,720 | $19 | $54 |
| Dexamethasone injection (steroid) An injection of dexamethasone sodium phosphate, a corticosteroid medication, administered in a dose of 1 milligram. |
3,012 | $0 | $1 |
| Anti-nausea injection (Aloxi/palonosetron) | 1,650 | $1 | $99 |
| Fluorouracil injection, 500 mg Administration of a 500 mg dose of fluorouracil medication via injection. |
1,070 | $2 | $14 |
| Injection, granisetron hydrochloride, 100 mcg | 1,040 | $0 | $10 |
| Office visit, established patient, complex (40-54 min) An office or outpatient visit for an existing patient lasting between 40 and 54 minutes. This level of service is determined by the total time spent on the date of the encounter. |
761 | $158 | $406 |
| Blood draw (venipuncture) Insertion of a needle into a vein to collect a blood sample. |
744 | $8 | $15 |
| Pegfilgrastim injection, 0.5 mg An injection of pegfilgrastim, a medication that stimulates the production of white blood cells. This specific code applies to the brand-name drug and excludes biosimilar versions. |
732 | $72 | $1,074 |
| Complete blood count (CBC) with differential An automated laboratory test that measures the levels of red blood cells, white blood cells, and platelets in the blood, including a breakdown of the different types of white blood cells. |
699 | $8 | $44 |
| Office visit, established patient (30-39 min) A follow-up office visit for an existing patient lasting between 30 and 39 minutes. The visit involves medical evaluation and management of the patient's condition. |
645 | $110 | $305 |
| Comprehensive metabolic blood panel A blood test that measures a group of chemicals, including glucose, electrolytes, and kidney and liver function markers. |
566 | $10 | $58 |
| Intravenous chemotherapy infusion, 1 hour or less Administration of chemotherapy medication directly into a vein. The procedure takes one hour or less to complete. |
537 | $139 | $514 |
| Intravenous injection of additional new drug or substance Administration of an additional new medication or substance directly into a vein. |
436 | $16 | $79 |
| Additional sequential IV infusion, 1 hour or less This code represents an additional intravenous infusion administered sequentially to a primary infusion. It covers the administration time of one hour or less. |
371 | $30 | $113 |
| Drug injection, under skin or into muscle A procedure involving the administration of a medication or substance via injection into the subcutaneous tissue or muscle. |
343 | $14 | $75 |
| Office visit, established patient (20-29 min) An office visit for an existing patient lasting between 20 and 29 minutes. The visit involves medical evaluation and management of the patient's condition. |
252 | $71 | $210 |
| Normal saline infusion, 250 cc Administration of 250 cubic centimeters of normal saline solution into a vein. This procedure involves the intravenous delivery of a sterile saltwater fluid. |
232 | $1 | $15 |
| Hospital follow-up visit, high complexity Subsequent hospital inpatient or observation care for an existing patient involving high-level medical decision making, with at least 50 minutes total time on the date of the encounter. |
203 | $107 | $347 |
| Intravenous infusion of new drug or substance, 1 hour or less This procedure involves administering a new medication or substance directly into a vein through an existing access site. The infusion is completed within one hour or less. |
159 | $69 | $251 |
| Non-hormonal chemotherapy injection This procedure involves administering non-hormonal anti-neoplastic chemotherapy medication via injection into the skin or muscle tissue. |
157 | $78 | $207 |
| Additional hour of intravenous chemotherapy This code represents the administration of chemotherapy medication into a vein for each additional hour beyond the initial period. |
145 | $29 | $111 |
| Diphenhydramine injection, up to 50 mg An injection of diphenhydramine hydrochloride, an antihistamine medication, administered in a dose of up to 50 milligrams. |
133 | $1 | $4 |
| New patient office visit, complex (60-74 min) | 117 | $195 | $569 |
| Ferritin level test (iron stores) A blood test that measures the level of ferritin, a protein that stores iron in the body. |
115 | $13 | $65 |
| Prolonged intravenous chemotherapy administration This procedure involves the administration of chemotherapy medication directly into a vein over an extended period. |
110 | $140 | $558 |
| Irrigation of implanted venous access device This procedure involves flushing an implanted venous access device to clear blockages or maintain patency. It ensures the device remains functional for delivering medications or fluids. |
103 | $26 | $90 |
| Intravenous infusion, 1 hour or less Administration of medication or fluid directly into a vein for therapeutic, preventive, or diagnostic purposes. The procedure lasts one hour or less. |
87 | $68 | $244 |
| Normal saline infusion, 1000 cc Administration of 1000 cc of normal saline solution into a vein. This procedure involves the intravenous delivery of a sterile saltwater solution. |
60 | $2 | $9 |
| On-body injector for subcutaneous injection A device is applied to the skin to automatically deliver a medication injection under the skin. |
58 | $19 | $91 |
| Carcinoembryonic antigen (CEA) level test A blood test that measures the level of carcinoembryonic antigen (CEA) protein. This test is used to monitor certain types of cancer. |
47 | $19 | $87 |
| Hospital follow-up visit, moderate complexity Follow-up hospital visit for an existing patient involving moderate medical decision making. The visit requires at least 35 minutes of time spent on the date of service. |
46 | $72 | $222 |
| Subcutaneous or intramuscular chemotherapy injection This procedure involves administering anti-cancer hormonal medication through an injection into the tissue under the skin or into a muscle. |
32 | $35 | $141 |
| Lactate dehydrogenase (LDH) level test A blood test that measures the amount of lactate dehydrogenase, an enzyme found in many body tissues. It helps assess tissue damage or disease. |
26 | $6 | $27 |
| Additional hour of intravenous hydration This code represents each additional hour of intravenous fluid administration beyond the initial hour. It is used to bill for extended hydration therapy. |
26 | $13 | $64 |
| Initial hospital admission, high complexity Initial hospital inpatient or observation care for a new patient involving high-level medical decision making, with at least 75 minutes total time on the date of the encounter. |
25 | $156 | $585 |
| Thyroid stimulating hormone (TSH) test A blood test that measures the level of thyroid stimulating hormone to evaluate thyroid function. |
22 | $16 | $70 |
| Basic metabolic blood panel A blood test that measures a group of basic chemicals, including total calcium levels. |
19 | $8 | $46 |
| Bone marrow biopsy and aspiration A procedure to remove a small sample of bone marrow and liquid for laboratory testing. The sample is analyzed to help diagnose various medical conditions. |
15 | $177 | $768 |
How to read this data: This reflects Medicare patients only (typically 65+). Payment amounts are what Medicare paid the provider, not your out-of-pocket cost. A higher procedure volume generally indicates more experience with that procedure.
2.0% high complexity
91.8% medium
6.2% routine
Industry Payment Transparency
Open Payments through 2024 ↗$280,342
Total received (2018-2024)
Avg $40,049/year across 7 years
Top 4% in CA for hematology & oncology
A higher payment rank reflects disclosed industry relationships (consulting, research, speaking) common among subspecialists — not wrongdoing.
78
Companies
666
Individual payments
All payments are legal and publicly reported · Not evidence of wrongdoing · How to interpret →
Payment profile
Industry payments classified by relationship type. Not all payments are equal — research and consulting reflect different relationships than speaking programs or meals.
Speaking / Promotional
Speaker programs, honoraria, and industry-sponsored educational events
$232,827 (83.1%)
Consulting
Expert advisory fees, typically reflecting recognized clinical expertise
$39,745 (14.2%)
Meals & Travel
Food, beverages, travel, and lodging — typically low-value
$7,769 (2.8%)
Payment trend by year
Annual totals from pharmaceutical and medical device companies.
2024
$55,179
2023
$75,995
2022
$33,893
2021
$42,384
2020
$17,157
2019
$22,581
2018
$33,153
Payments by company (2024)
Consulting
Speaking
Meals & Travel
Research
E.R. Squibb & Sons, L.L.C.
$29,679
AstraZeneca Pharmaceuticals LP
$8,115
ABBVIE INC.
$3,865
Mirati Therapeutics, Inc.
$3,361
Amgen Inc.
$2,922
Incyte Corporation
$2,729
Takeda Pharmaceuticals U.S.A., Inc.
$2,151
Janssen Biotech, Inc.
$282
Merck Sharp & Dohme LLC
$251
Celgene Corporation
$240
PFIZER INC.
$184
Novartis Pharmaceuticals Corporation
$167
Genentech, Inc.
$123
Astellas Pharma US Inc
$106
GENZYME CORPORATION
$85
SpringWorks Therapeutics, Inc.
$83
SEAGEN INC.
$78
Genentech USA, Inc.
$68
Bayer Healthcare Pharmaceuticals Inc.
$57
ADC Therapeutics America, Inc.
$54
Coherus Biosciences Inc.
$50
ARRAY BIOPHARMA INC
$48
Myriad Genetic Laboratories, Inc.
$46
RECORDATI_RARE_DISEASES_INC.
$42
Agios Pharmaceuticals, Inc.
$38
Kite Pharma, Inc.
$35
Exelixis Inc.
$30
PUMA BIOTECHNOLOGY, INC.
$29
Ipsen Biopharmaceuticals, Inc
$26
Lilly USA, LLC
$26
GlaxoSmithKline, LLC.
$25
Tactile Systems Technology Inc
$25
Eisai Inc.
$24
Spectrum Pharmaceuticals Inc.
$22
ARGENX US, INC.
$22
Deciphera Pharmaceuticals Inc.
$21
Gilead Sciences, Inc.
$21
Azurity Pharmaceuticals, Inc.
$19
Novocure Inc.
$15
Karyopharm Therapeutics Inc.
$14
Top 3 companies account for 75.5% of 2024 payments
All-time payments by company (2018-2024) ›
E.R. Squibb & Sons, L.L.C.
$109,245
Mirati Therapeutics, Inc.
$41,999
AstraZeneca Pharmaceuticals LP
$40,489
Takeda Pharmaceuticals U.S.A., Inc.
$34,572
Amgen Inc.
$13,007
Celgene Corporation
$10,609
ABBVIE INC.
$8,693
Seattle Genetics, Inc.
$5,342
Incyte Corporation
$3,390
AstraZeneca UK Limited
$2,220
Janssen Biotech, Inc.
$1,977
Rigel Pharmaceuticals, Inc.
$1,200
Puma Biotechnology, Inc.
$1,125
Bayer HealthCare Pharmaceuticals Inc.
$1,057
Merck Sharp & Dohme LLC
$392
GENZYME CORPORATION
$390
PFIZER INC.
$383
Novartis Pharmaceuticals Corporation
$339
Kite Pharma, Inc.
$311
Lilly USA, LLC
$222
Seagen Inc.
$206
Astellas Pharma US Inc
$201
Genentech, Inc.
$143
Daiichi Sankyo Inc.
$136
Allergan Inc.
$135
Exelixis Inc.
$133
Nevro Corp.
$127
Genentech USA, Inc.
$125
Pharmacyclics LLC, An AbbVie Company
$121
ARRAY BIOPHARMA INC
$106
Array BioPharma Inc.
$102
GlaxoSmithKline, LLC.
$101
Pharmacyclics LLC, an AbbVie Company
$86
SpringWorks Therapeutics, Inc.
$83
SEAGEN INC.
$78
TAIHO ONCOLOGY, INC.
$78
Bayer Healthcare Pharmaceuticals Inc.
$77
Myriad Genetic Laboratories, Inc.
$70
Gilead Sciences, Inc.
$70
TerSera Therapeutics LLC
$70
RECORDATI_RARE_DISEASES_INC.
$60
AbbVie, Inc.
$55
Merck Sharp & Dohme Corporation
$55
ADC Therapeutics America, Inc.
$54
Agios Pharmaceuticals, Inc.
$53
Coherus Biosciences Inc.
$50
SOBI, INC
$48
Tactile Systems Technology Inc
$41
EMD Serono, Inc.
$39
Alnylam Pharmaceuticals Inc.
$38
Novocure Inc.
$34
PORTOLA PHARMACEUTICALS, INC.
$32
PUMA BIOTECHNOLOGY, INC.
$29
AbbVie Inc.
$29
Sumitomo Pharma America, Inc.
$28
Acrotech Biopharma LLC
$28
Ipsen Biopharmaceuticals, Inc
$26
Blueprint Medicines Corporation
$26
Jazz Pharmaceuticals Inc.
$26
TESARO, Inc.
$26
Eisai Inc.
$24
Myovant Sciences Inc.
$23
Foundation Medicine, Inc.
$23
Spectrum Pharmaceuticals Inc.
$22
JAZZ PHARMACEUTICALS INC.
$22
ARGENX US, INC.
$22
Deciphera Pharmaceuticals Inc.
$21
EISAI INC.
$21
Clovis Oncology, Inc.
$20
Octapharma USA, Inc.
$20
Azurity Pharmaceuticals, Inc.
$19
CTI BioPharma Corp.
$19
Sun Pharmaceutical Industries Inc.
$18
AMAG Pharmaceuticals, Inc.
$18
BTG International, Inc.
$18
Mylan Pharmaceuticals Inc.
$17
Teva Pharmaceuticals USA, Inc.
$17
Karyopharm Therapeutics Inc.
$14
Top 3 companies account for 68.4% of all-time payments
Associated products mentioned in payments ›
ADCETRIS · AFINITOR · AKEEGA · ALIMTA · ANDEXXA · Abraxane · Avastin · BAVENCIO · BELEODAQ · BENDEKA · BLENREP · BOSULIF · BRACAnalysis CDx · BRAFTOVI · Blincyto · Braftovi · CABLIVI · CABOMETYX · CALQUENCE · CARVYKTI · CYRAMZA · Cabometyx · Columvi · DARZALEX · Doptelet · ELIQUIS · ELITEK · ELREXFIO · EMPLICITI · ENHERTU · EPKINLY · ERLEADA · EVENITY · Enhertu · Erleada · FERAHEME · FRUZAQLA · Flexitouch Plus · Fulphila · GAVRETO · GAZYVA · GIVLAARI · IBRANCE · ICLUSIG · IMBRUVICA · IMFINZI · INFLECTRA · INJECTAFER · INLYTA · INREBIC · Imbruvica · Inrebic · Itovebi · JAKAFI · JEMPERLI · JEVTANA · KANJINTI · KEYTRUDA · KISQALI · KRAZATI · Kyprolis · LIBTAYO · LONSURF · LOQTORZI · LORBRENA · LUMAKRAS · LUTATHERA · LYNPARZA · Lenvima · Leqembi · Lupron · Lupron Depot · MEKINIST · MONJUVI · MYLOTARG · NINLARO · Nerlynx · Neulasta · Non-Covered Product · Nplate · Nubeqa · OCTAGAM IMMUNE GLOBULIN (HUMAN) · ODOMZO · OGSIVEO · OPDIVO · OPDUALAG · ORGOVYX · Ocrevus · Oncology · Onivyde · Optune · PADCEV · PLUVICTO · PRECISETUMOR · PROLARIS · Padcev · Pomalyst · Prolia · QINLOCK · REBLOZYL · ROLVEDON · RYBREVANT · Revlimid · Rubraca · SARCLISA · SCEMBLIX · STRATTICE · SUTENT · SYLVANT · Senza Spinal Cord Stimulation System · Stivarga · TAGRISSO · TASIGNA · TECENTRIQ · TEPMETKO · TIBSOVO · TIVDAK · TUKYSA · Tavalisse · Udenyca · VENCLEXTA · VERZENIO · VIVIMUSTA · VORAXAZE · VOTRIENT · VPRIV · VYVGART HYTRULO · Venclexta · Vitrakvi · Vonjo · Vyloy · XALKORI · XOSPATA · XPOVIO · XTANDI · Xtandi · Yescarta · ZEJULA · ZEPZELCA · ZOLADEX
Should you be concerned? Payments from pharmaceutical and device companies are legal and common — 57% of U.S. physicians receive at least one. They often reflect legitimate consulting, research, or education. What matters is whether a recommended drug or device appears in your doctor's payment records. If so, consider asking your doctor about it. How to interpret this data →
The majority of payments (83%) are for speaking programs and promotional activities, which reflect participation in industry-sponsored educational or marketing events. This is common in hematology & oncology and does not inherently indicate bias, but patients may wish to be aware. Total industry engagement is in the top 4% for hematology & oncology in CA.
Geographic Context
Hematology & oncology specialists within 10 mi
103
Per 100K population
8.9
County median income
$125,727
Nearest hospital
JOHN MUIR MEDICAL CENTER - WALNUT CREEK CAMPUS
0.0 mi
0.0 mi
Data Sources
| Provider Registry | ✓ NPPES | Weekly updates |
| Medicare Enrollment | ✓ PECOS | Monthly updates |
| Practice Data | ✓ Medicare Util. | Annual (CY lag) |
| Industry Payments | ✓ Open Payments | CY 2024 |
| Disciplinary History | — Not public | N/A |
This provider has data in 4 of 4 available federal datasets, with a Data Coverage level of Very High. This reflects how much public data is available about a provider. How we calculate this →
Summary
Dr. Johl is a mixed practice specialist, with above-average Medicare volume (top 10% in CA), with speaking/promotional industry engagement in the top 4% of CA peers, with 20 years of NPI registration.
This summary is auto-generated from federal data, describing data availability and patterns. Read our methodology →
Frequently Asked Questions
Is Dr. Johl experienced with pembrolizumab injection (keytruda)?
Based on Medicare claims data, Dr. Johl performed 21,000 pembrolizumab injection (keytruda) services. Research suggests that higher procedure volume is often associated with better outcomes, particularly for complex procedures. Note that Medicare data only captures patients aged 65 and older, so the total practice volume across all patients is likely higher.
Does Dr. Johl receive payments from pharmaceutical companies?
Yes. Dr. Johl received a total of $280,342 from 78 companies across 666 individual payments. These payments are legal, publicly disclosed under the federal Sunshine Act, and common among physicians — 57% of all U.S. physicians receive at least one industry payment. Patients may wish to ask their doctor about these relationships, especially if a recommended drug or device appears in the payment records.
How do Dr. Johl's costs compare to other hematology & oncology specialists in Walnut Creek?
Dr. Johl's average Medicare payment per service is $27. Note that these figures represent what Medicare pays, not your out-of-pocket cost, which depends on your specific insurance plan and deductible. Procedure-level data above shows both what was submitted and what Medicare paid for each service type.
What does Data Coverage mean?
Data Coverage (currently Very High for Dr. Johl) measures how much public federal data is available about a provider. It is not a quality rating. A "Very High" or "High" level means the provider has data across multiple federal sources (NPPES, PECOS, Medicare Utilization, Open Payments), indicating a long track record of practice, Medicare participation, and industry disclosure. A "Low" or "Moderate" level may simply mean the provider is newer, does not see Medicare patients, or has not received any industry payments — none of which are inherently negative. Read our full methodology →
Is this data up to date?
Each data source has its own update cycle. Provider registry data (NPPES) is updated weekly. Medicare enrollment (PECOS) is updated monthly. Medicare practice data has a ~2 year lag — the most recent available is typically 2 years prior. Industry payment data (Open Payments) is published annually, usually in June, covering the prior calendar year. We display the data date prominently on each section so you always know how current it is. See our data freshness policy →
Explore related providers
Same specialty & city
Hematology & Oncology Specialists in Walnut Creek
Browse hematology & oncology specialists in Walnut Creek ranked by procedure volume and transparency data.
Highest volume
Top Hematology & Oncology Specialists in CA
Hematology & oncology specialists ranked by total Medicare services performed statewide.
Industry payments
Pharma Payments to Hematology & Oncology Specialists in CA
Which CA hematology & oncology specialists receive the most from drug and device companies.
By company
E.R. Squibb & Sons, L.L.C. Payments to Doctors
See all physicians who received payments from E.R. Squibb & Sons, L.L.C.
By company
Mirati Therapeutics, Inc. Payments to Doctors
See all physicians who received payments from Mirati Therapeutics, Inc.
By company
AstraZeneca Pharmaceuticals LP Payments to Doctors
See all physicians who received payments from AstraZeneca Pharmaceuticals LP.
About this page
All data on this page is sourced verbatim from public federal records published by the U.S. Centers for Medicare & Medicaid Services (CMS): NPPES ↗, Open Payments ↗, Medicare Provider Utilization ↗, and PECOS. Publication is mandated by the Physician Payments Sunshine Act (§6002 ACA, 42 U.S.C. §1320a-7h) and the Freedom of Information Act.
This page is not medical advice, an endorsement, a recommendation, or a quality rating. Data Coverage reflects data completeness — how much federal information exists for this provider — not clinical performance, patient outcomes, or quality of care. Always verify information directly with the provider and consult a licensed clinician before making medical decisions.
Provider corrections: Provider portal · Privacy questions: Privacy Policy · Terms: Terms of Use · Methodology: Methodology